Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Infectious Diseases

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/588794PMID 18513146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation

  2008cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

  2008cited by this paper
• Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

  2007cited by this paper
• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  2007cited by this paper
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

  2007cited by this paper
• Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.

  2007cited by this paper
• 46th Interscience Conference on Antimicrobial Agents and Chemotherapy

  2006cited by this paper
• IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION

  2005influential reference

• Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator

  2025cites this paper
• Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

  2024cites this paper
• Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat

  2023cites this paper
• Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.

  2023cites this paper
• Combined Oral Contraceptives As Victims of Drug Interactions

  2023cites this paper
• How Science Is Driving Regulatory Guidances.

  2021cites this paper
• When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations

  2021cites this paper
• PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates

  2021cites this paper
• Pharmacokinetic drug interactions of integrase strand transfer inhibitors

  2021cites this paper
• Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human

  2020cites this paper
• Infection and Drug Resistance Dovepress

  2019cites this paper
• Role of Drug Metabolic Enzymes and Transporters in Drug-Drug Interactions Between Antiretroviral and Antituberculosis Drugs

  2018cites this paper
• Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir

  2018cites this paper
• A safety evaluation of raltegravir for the treatment of HIV

  2018cites this paper
• Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches

  2018cites this paper
• Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery

  2018cites this paper
• Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

  2017cites this paper
• Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose

  2016cites this paper
• Assessment of pharmacokinetic drug‐drug interaction between pradigastat and atazanavir or probenecid

  2016cites this paper
• Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice

  2016cites this paper
• The role of therapeutic drug monitoring and pharmacogenetic testing in the management of HIV infection: a review.

  2015cites this paper
• Reconsidering first-line antiretroviral therapy in the pregnant population

  2015cites this paper
• Evaluation Vitro In Inhibition of Major Drug Transporters : an Clinical Drug Interactions through Raltegravir Has a Low Propensity To Cause

  2014cites this paper
• Long-term efficacy and safety of raltegravir in the management of HIV infection

  2014cites this paper
• Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

  2014cites this paper
• Raltegravir Pharmacokinetics During Pregnancy

  2014cites this paper
• Integrating Integrase Inhibitors Into an Antiretroviral Regimen

  2014cites this paper
• Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults

  2013cites this paper
• The place of raltegravir in the clinical management of HIV-1 infection

  2013cites this paper
• Pharmacology of HIV Integrase Inhibitors

  2013cites this paper
• Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples

  2013cites this paper
• Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents

  2013cites this paper
• [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)].

  2013cites this paper
• A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

  2013cites this paper
• Pharmacokinetics of the combination raltegravir/atazanavir in HIV‐1‐infected patients

  2013cites this paper
• Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics

  2013cites this paper
• Variability of Raltegravir Plasma Levels in the Clinical Setting

  2013cites this paper
• Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation

  2013cites this paper
• Pharmacology of HIV integrase inhibitors

  2012cites this paper
• Raltegravir – an integrase inhibitor for antiretroviral therapy in HIV-1 infection

  2012cites this paper
• Role of Raltegravir in HIV-1 Management

  2012cites this paper
• Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals

  2012cites this paper
• Population pharmacokinetics and pharmacogenetics of antiretroviral drugs

  2012cites this paper
• Population Pharmacokinetic Analysis and Pharmacogenetics

  2012cites this paper
• Stable Virologic Suppression during Raltegravir plus Atazanavir Dual-Therapy Taken Every other Day: A Case Report

  2012cites this paper
• Update on Raltegravir and the Development of New Integrase Strand Transfer Inhibitors

  2012cites this paper
• A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

  2012cites this paper
• Should a protease inhibitor be standard of care for HIV postexposure prophylaxis ?

  2011cites this paper
• Role of raltegravir in the management of HIV-1 infection

  2011cites this paper
• Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

  2011cites this paper
• Severe insomnia related to high concentrations of raltegravir.

  2011cites this paper
• Clinical Pharmacology Profile of Raltegravir, an HIV‐1 Integrase Strand Transfer Inhibitor

  2011cites this paper
• Drug Interactions With Antiretrovirals for HIV Infection

  2011cites this paper
• Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management

  2011cites this paper
• Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

  2010cites this paper
• Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures

  2010cites this paper
• Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers

  2010influential citation
• Novel Antiretroviral Combinations in Treatment-Experienced Patients with HIV Infection

  2010cites this paper
• Integrase Inhibitors: A Novel Class of Antiretroviral Agents

  2010cites this paper
• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  2010cites this paper
• Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

  2010cites this paper
• Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress Signaling Pathways

  2010cites this paper
• Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

  2010cites this paper
• Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

  2010cites this paper
• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

  2010cites this paper
• [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)].

  2010cites this paper
• Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

  2010cites this paper
• HIV treatment: A clinical pharmacology perspective.

  2010cites this paper
• Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers

  2010cites this paper
• Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients

  2010cites this paper
• Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients

  2010cites this paper
• Effect of Raltegravir on the Pharmacokinetics of Methadone

  2010cites this paper
• Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies

  2010cites this paper
• Raltegravir: The evidence of its therapeutic value in HIV-1 infection

  2009cites this paper
• Raltegravir: molecular basis of its mechanism of action

  2009cites this paper
• Drug-drug interactions with raltegravir

  2009influential citation
• Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

  2009influential citation
• The Effect of Raltegravir on the Glucuronidation of Lamotrigine

  2009cites this paper
• Clinical pharmacology, efficacy and safety of atazanavir: a review

  2009cites this paper
• Raltegravir: Its use in the Treatment of HIV Infection

  2009cites this paper
• Drug–drug interactions involving new antiretroviral drugs and drug classes

  2009cites this paper
• New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir

  2009cites this paper
• Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants

  2009cites this paper
• Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

  2009cites this paper
• A Review of Raltegravir and its Use in HIV-1 Infection

  2009cites this paper
• Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults

  2009cites this paper
• Clinicalpharmacology,efficacy andsafetyofatazanavir:areview

  2009cites this paper
• Raltegravir: first integrase inhibitor for the treatment of HIV infection

  2009cites this paper
• Emerging Pharmacology: Inhibitors of Human

  2009cites this paper
• Raltegravir

  2009cites this paper
• [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

  2009cites this paper
• Integrase inhibitors in salvage therapy regimens for HIV-1 infection

  2009cites this paper
• Raltegravir: the first HIV type 1 integrase inhibitor.

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper
• No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo

  2008cites this paper
• Raltegravir, an HIV-1 integrase inhibitor for HIV infection.

  2008cites this paper
• Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

  2008cites this paper
• Infection and Drug Resistance Dovepress Raltegravir in Combination with Other Antiretroviral Agents for the Treatment of Hiv Infection

  year unknowncites this paper
• Hiv/aids -research and Palliative Care Dovepress Role of Raltegravir in the Management of Hiv-1 Infection

  year unknowncites this paper
• 50th Anniversary Celebration Collection — Minireview Combined Oral Contraceptives As Victims of Drug Interactions S

  year unknowninfluential citation